Strong Q3 results. FY outlook confirmed.

Massive beat in Q3. FY estimates are likely to be increased.

Decent beat in Q3 Sales- FY guidance lifted.

Novartis acquires a US-based neuroscience company for $12bn.

Strong beat at Operating level notably thanks to Dupixent.

Q3 sales mark an improvement in momentum.